单位:[1]Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China.[2]Beijing Key Laboratory of Bio-Characteristic Profiling for Evaluation of Rational Drug Use, Beijing, People's Republic of China.[3]Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.医技科室药学部首都医科大学附属北京友谊医院
第一作者单位:[1]Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China.[2]Beijing Key Laboratory of Bio-Characteristic Profiling for Evaluation of Rational Drug Use, Beijing, People's Republic of China.
通讯作者:
通讯机构:[1]Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China.[2]Beijing Key Laboratory of Bio-Characteristic Profiling for Evaluation of Rational Drug Use, Beijing, People's Republic of China.[*1]Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi-Road, Haidian District, Beijing, 10038, People’s Republic of China
推荐引用方式(GB/T 7714):
Bao Li,Zhang Ying,Yan Sichao,et al.Lysophosphatidylcholine (17:0) Improves HFD-Induced Hyperglycemia & Insulin Resistance: A Mechanistic Mice Model Study[J].Diabetes, Metabolic Syndrome And Obesity : Targets And Therapy.2022,15:3511-3517.doi:10.2147/DMSO.S371370.
APA:
Bao Li,Zhang Ying,Yan Sichao,Yan Dan&Jiang Dechun.(2022).Lysophosphatidylcholine (17:0) Improves HFD-Induced Hyperglycemia & Insulin Resistance: A Mechanistic Mice Model Study.Diabetes, Metabolic Syndrome And Obesity : Targets And Therapy,15,
MLA:
Bao Li,et al."Lysophosphatidylcholine (17:0) Improves HFD-Induced Hyperglycemia & Insulin Resistance: A Mechanistic Mice Model Study".Diabetes, Metabolic Syndrome And Obesity : Targets And Therapy 15.(2022):3511-3517